Press Room

7 December 2022

28 April 2022

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

8 December 2021

New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score^® Test to Inform Clinical Decision-making

1 December 2021

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test

20 May 2021

New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score^® Test in Node-Positive Early-Stage Breast Cancer

24 March 2021

New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score^® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer

9 December 2020

RxPONDER Study Results Demonstrate that the Oncotype DX^® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

2 October 2020

New Real-World Evidence Further Demonstrates the Clinical Utility of the Oncotype DX Breast Recurrence Score^® Test, Beyond Clinical Risk Factors, in Guiding Chemotherapy Treatment Decisions in Patients with Early-stage Breast Cancer

29 May 2020

New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score^® Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients

14 May 2020

New Oncotype DX Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results

12 December 2019

New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer

30 September 2019

New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment

21 August 2019

New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy for Node-Negative and Node-Positive Early-Stage Breast Cancer

21 June 2019

German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test

4 June 2019

Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

3 June 2019

Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score Test in Node-negative Breast Cancer

25 March 2019

New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score Test to Target Chemotherapy